Advancements in the Development of ADC-technology for Cancer Treatment
In an article published in Future Drug Discovery, Justyna Mysliwy, Bioconjugation Team Leader at Iksuda Therapeutics, writes about the...
Loncastuximab Tesirine Shows Early Promise in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Loncastuximab tesirine, also known as ADCT-402, an investigational antibody-drug conjugate being developed by ADC Therapeutics, showed signs of clinical...
Ultrafiltration and Diafiltration in the Clearance of Solvents and Small Molecule Impurities in ADC...
In a new article, published in the October 6, 2019 edition of Biotechnology Progress, Travis Gates, Yaqi Fara Lyu,...
Highlights in Development: September 2019
In September 2019, a number of articles discussing antibody-drug conjugates were published in a variety of journals. Here is...
ADC-based Conditioning with Platelet-directed HSC-based FVIII Gene Therapy Shows Promise in Hemophilia Treatment
Gene therapy for hemophilia, a condition in which the ability of the blood to clot is severely reduced, as...
Enabling Heterobifunctional, Dual “Click,” Antibody Modification via Microbial Transglutaminase
With 5 approved and commercially available antibody-drug conjugates, this class of therapeutics, combining the efficacy of small-molecule therapeutics with...
Identifying Regulators of Antibody–drug Conjugate Toxicity
Antibody–drug conjugates or ADCs selectively deliver a a cytotoxic payload to target cancer cells, making them important anti-cancer therapeutics....
Using a Hydrophilic Spacer to Reduce Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates
In the development of novel drug conjugates alternatives to monoclonal antibodies (mAbs) have started to emerge. While antibodies have...
Using Middle-Down Mass Spectrometry to Identify the Drug Conjugation Site of a Site-Specific Antibody-Drug-Conjugate
Antibody–drug conjugates are among the fastest growing classes of anti-cancer therapeutics. With the 5 approved and commercially available agents, and nearly...
A Superglue for ADCs: Connecting the Cytsteine Residues of a Tumor-sensing Antibody to a...
The Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU) hve developed an innovative technology designed to make...
